KYMR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KYMR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Kymera Therapeutics's net current asset value per share for the quarter that ended in Mar. 2024 was $6.20.
The historical rank and industry rank for Kymera Therapeutics's Net Current Asset Value or its related term are showing as below:
During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Kymera Therapeutics was 27.80. The lowest was 3.23. And the median was 6.48.
The historical data trend for Kymera Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Net Current Asset Value | Get a 7-Day Free Trial | -3.25 | 2.23 | 5.92 | 5.57 | 4.04 |
Kymera Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net Current Asset Value | Get a 7-Day Free Trial | 4.70 | 4.31 | 3.95 | 4.04 | 6.20 |
For the Biotechnology subindustry, Kymera Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Kymera Therapeutics's Price-to-Net-Current-Asset-Value falls into.
Kymera Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as
Net Current Asset Value Per Share | (A: Dec. 2023 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (405.317 | - | 180.788 | - | 0 | - | 0) | / | 55.5853 |
= | 4.04 |
Kymera Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as
Net Current Asset Value Per Share | (Q: Mar. 2024 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (537.253 | - | 157.048 | - | 0 | - | 0) | / | 61.3531 |
= | 6.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics (NAS:KYMR) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of Kymera Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey W. Albers | director | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Ellen Chiniara | officer: Chief Legal Officer | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Jeremy G Chadwick | officer: Chief Operating Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472 |
Bruce N. Jacobs | officer: Chief Financial Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Bruce Booth | director | 890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
Atlas Venture Fund X, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Victor Sandor | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
Leigh Morgan | director | KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472 |
John Maraganore | director | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Nello Mainolfi | director, officer: President and CEO | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Jared Gollob | officer: Chief Medical Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Richard Chesworth | officer: Chief Scientific Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Atlas Venture Associates X, L.p. | 10 percent owner | 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139 |
Elaine Caughey | officer: Chief Business Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
From GuruFocus
By GuruFocus Research • 11-02-2023
By Value_Insider Value_Insider • 12-12-2022
By GuruFocus Research • 01-24-2024
By Marketwired • 09-18-2023
By Stock market mentor Stock market mentor • 01-04-2023
By Marketwired • 06-22-2023
By Marketwired • 11-02-2023
By sperokesalga sperokesalga • 06-09-2023
By Marketwired • 07-27-2023
By Value_Insider Value_Insider • 12-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.